Trefoil Therapeutics

No article has been written about this topic yet.
Paste a URL about this topic to auto-extract knowledge.
Visit our Writing Guide for help on how to write about a topic,
and check out an example of a well filled out topic page.

No article has been written about this topic yet.
Be the first one to add some text.

Loading AI-assisted edit mode...

Timeline

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Trefoil Therapeutics Series A round, July 2019
28,000,000
July 2019
1 Result
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioSpace
November 12, 2020
BioSpace
Trefoil Therapeutics, which is developing first-in-class regenerative treatments for corneal diseases, announced today it has received the 'People's Choice' award at the inaugural Eyecelerator virtual conference. The company's lead product, an engineered fibroblast growth factor 1 (FGF-1, TTHX1114) administered by intracameral (behind the cornea) injection, recently entered a Phase 1/2 clinical trial for the treatment of endot
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.